Global Nonalcoholic Steatohepatitis (NASH) Treatment Market US$ 19.

8 Billion by 2025

The global nonalcoholic steatohepatitis (NASH) treatment market is estimated to reach US$ 19.8 Billion in 2025,
expanding at a CAGR of 10.0% from 2017 to 2025, mainly driven by expected approval of Aramchol, Elafibranor,
Obeticholic acid, and Simtuzumab, and introduction of several new high-priced products. Moreover, combination
therapies are likely to dominate the global market over the forecast period.

https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/

Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease (NAFLD), is defined as the
presence of hepatic steatosis with inflammation and hepatocyte injury. NAFLD spans a spectrum of clinicopathologic
entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.
Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis
methods for NAFLD helps in the prediction of NASH occurrence. The prevalence of NASH is increasing rapidly in
parallel with that of Type 2 diabetes and obesity. NASH is an increasingly common chronic liver disease with
worldwide distribution that is closely associated with diabetes and obesity, which have both reached epidemic
proportions. It is estimated that there are at least 1.46 billion obese adults worldwide. Approximately 6 million
individuals in the USA are estimated to have progressed to NASH and some 600,000 to NASH-related cirrhosis. In
the United States, NASH-associated cirrhosis is currently the third most frequent reason for liver transplantation and
is predicted to become the leading cause and it is projected to overtake Hepatitis C as the leading cause of liver
transplants in the U.S. by 2020.

No medicines have been approved to treat NAFLD and NASH. However, some studies suggest that pioglitazone
(Actos), a medicine for type 2 diabetes, improves NASH in patients without diabetes. Targets for therapy are insulin
resistance and oxidative stress. Antioxidants and antifibrotic agents, such as vitamin E and pentoxifylline, have not
been approved for NASH/NAFLD treatment. Lifestyle changes are encouraged for patients with NASH, including
reducing body weight, following a balanced diet, increasing physical activity, and avoiding alcohol. Lifestyle changes
are critical in any attempt to reverse the course of NAFLD/NASH, and an evidence-based approved drug therapy for
NAFLD/NASH is not available at present. The NASH therapies in clinical pipeline (phase II and III) include Aramchol,
ARI 3037MO, BMS-986036, Cenicriviroc (TBR-652), Elafibranor (GF-505), Emricasan (IDN-6556), GR-MD-02, GS-4997,
Liraglutide (Victoza/Saxenda), Obeticholic acid (OCA/Ocaliva), Simtuzumab (GS-6624), Tipelukast, and Volixibat (SHP
626).

Visit Nonalcoholic Steatohepatitis Treatment Market by Drug Type (Pioglitazone and Type 2 Diabetes Mellitus
(T2DM) Medicines, Vitamin E, Others), Pipeline Analysis (Phase III Drugs - Aramchol (Arachidyl Amido Cholanoic
Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-
6624), Others), and Phase I and II Drugs 2017-2025. The global nonalcoholic steatohepatitis treatment market report
provides market size (Revenue USD Million 2014 to 2025), market share, market trends and forecasts growth trends
(CAGR%, 2016 to 2020). The global nonalcoholic steatohepatitis treatment market research report is segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players
operating in the global nonalcoholic steatohepatitis treatment market and included in this report are AstraZeneca
plc, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences Inc., Immuron Ltd., Intercept
Pharmaceuticals Inc., Novartis, Pfizer, Sumitomo Dainippon Pharma, Tobira Therapeutics Inc., and Zydus Cadila.

1. Drug Type
1.1. Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines
1.2. Vitamin E
1.3. Others

2. Pipeline Analysis
 2.1. Phase III Drugs
2.1.1. Aramchol (Arachidyl Amido Cholanoic Acid)
2.1.2. Elafibranor (GFT505)
2.1.3. Emricasan (IDN-6556, PF-03491390)
2.1.4. Obeticholic Acid (OCA/Ocaliva)
2.1.5. Simtuzumab (GS-6624)
2.1.6. Others
2.2. Phase I and II Drugs

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. AstraZeneca plc
4.2. Conatus Pharmaceuticals
4.3. Galmed Pharmaceuticals
4.4. Genfit Sa
4.5. Gilead Sciences Inc.
4.6. Immuron Ltd.
4.7. Intercept Pharmaceuticals, Inc.
4.8. Novartis
4.9. Pfizer
4.10. Sumitomo Dainippon Pharma
4.11. Tobira Therapeutics, Inc.
4.12. Zydus Cadila

To request Table of Contents and Sample Pages of this report visit:

https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting
grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client
assignments targeted at clients specific business objectives, information needs, time frame and budget. Please
contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com